Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration

Autor: Freeman, William R., Bandello, Francesco, Souied, Eric, Guymer, Robyn H., Garg, Sunir J., Chen, Fred K., Rich, Ryan, Holz, Frank G., Patel, Sunil S., Kim, Kimmie, López, Francisco J., Chen, Fred, Guymer, Robyn, Korobelnik, Jean-Francois, Souied, Eric, Holz, Frank, Ziemssen, Focke, Bandello, Francesco, Campos, Emilio, Grignolo/Eandi, Chiara, Midena, Edoardo, Peiretti, Enrico, Staurenghi, Giovanni, Viola, Francesco, Bailey, Clare, Esposti, Simona Degli, Jackson, Timothy, Menon, Geeta, Pagliarini, Sergio, Quhill, Fahd, Antoszyk, Andrew, Brooks, Logan, Callanan, David, Csaky, Karl, Edwards, Albert, Eichenbaum, David, Freeman, William, Garg, Sunir, Ghuman, Avtar Thomas, Gonzalez, Victor, Gupta, Sunil, Hamilton, Richard, Khurana, Rahul, Kunimoto, Derek, Kuppermann, Baruch, Lauer, Andreas, Lee, Seong Young, Maturi, Raj, Patel, Sunil, Reddy, Rahul, Rich, Ryan, Rivellese, Mark, Rose, Steven, Segal, Zachary, Wong, Robert
Zdroj: Ophthalmology Retina; 20230101, Issue: Preprints
Abstrakt: To evaluate the safety and efficacy of repeat injections of the Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400-μg brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Databáze: Supplemental Index